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Chronic kidney disease (CKD) patients, characterized by traditional and nontraditional risk factors, are prone to develop
atheromatosis and thus cardiovascular events and mortality. The angiogenesis of the adventitial vasa vasorum (aVV) surrounding
the carotid has been described as the atheromatosis initiator.Therefore, the aim of the study was to (1) evaluate if the carotid aVV in
CKD patients increases in comparison to its physiological value of healthy patients; (2) explore which traditional or nontraditional
risk factor including inflammation, bone and mineral metabolism, and anemia could be related to the aVV angiogenesis. CKD
patients without previous cardiovascular events (44, stages 3-4; 37, stage 5D) and 65 healthy subjects were compared. The carotid
aVV and the intima-media thickness (cIMT) were evaluated by ultrasound. CKD patients at stages 3-4 showed higher aVV of
the right carotid artery even after adjusting for age. Importantly, a multiple linear regression model showed hemoglobin levels >
12.5 g/dL as the factor for an estimated higher aVV of the right carotid artery. In conclusion, the association of hemoglobin with
higher aVV could suggest the role of high hemoglobin in the higher incidence of adverse cardiovascular outcomes in CKD patients.
1. Introduction
Chronic kidney disease (CKD) has been reported as a
major risk factor for cardiovascular (CV) disease [1]. Indeed,
CKD patients at all stages demonstrate a marked increase
in the incidence of CV events and CV disease mortality
in comparison with age- and sex-matched subjects of the
general population [2] and, in particular, in dialysis patients,
CV mortality rate is 10 times higher than that for the general
population [3, 4]. This high incidence is due to the fact that
not only are patients with CKD affected by traditional risk
factors including hypertension, diabetes, dyslipidemia, and
smoking [5], but they are also affected by nontraditional risk
factors including inflammation, altered bone and mineral
metabolism, anemia, and albuminuria. Both traditional [6, 7]
and nontraditional risk factors [8–11] are associated with the
impairment of the endothelial function and the inflammatory
response [12], key steps in the development of atherosclerosis,
plaque progression, and a higher risk of CV events.
Challenging the common belief that subclinical endothe-
lial dysfunction has been considered the earliest step in the
chronic inflammation of the vessel wall, studies byHerrmann
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et al. demonstrated conclusively that, during pathological
conditions, increases in the density of adventitial vasa vaso-
rum (VV), the plexus of physiologicalmicrovessels surround-
ing the adventitial layer, precede endothelial dysfunction [13].
Inflammation has been strongly related to VV neoan-
giogenesis [14]. Indeed, inflammation is associated with the
recruitment of circulating inflammatory cells as neutrophils,
macrophages, and lymphocytes which secrete proangiogenic
factors including cytokines and the well characterized signal-
ing molecule Vascular Endothelial Growth Factor (VEGF)
[15, 16]. Together with inflammation, elevated levels of
parathyroid hormone (PTH), lower levels of vitamin D, and
anemia, all common features of CKD, have been recognized
as proangiogenic stimuli. Specifically, recent experimental
animal studies associated PTH treatment with increased
angiogenesis in both the ischemic brain and the infarcted
heart [17, 18]. Equally important in the angiogenesis process
is the evidence of the involvement of vitamin D. Oikawa
et al. showed that active vitamin D, 1𝛼,25-dihydroxyvitamin
D3 (1,25D), was highly effective in inhibiting angiogenesis in
a dose-dependent manner in chick embryo chorioallantoic
membranes [19]. Consequently, while several lines of evi-
dence support the efficacy of 1,25D to suppress neoangio-
genesis through strong anti-VEGF properties [20–22], others
demonstrated that calcitriol exerts antiangiogenic properties
in a VEGF-independent manner. Indeed, in the retina, cal-
citriol suppresses neovascularization through the inhibition
of the endothelial cells proliferation and sprouting [23].
Additionally, a third feature of CKD that could be involved in
angiogenesis and therefore in the increases of the adventitial
VV is anemia. In a study of 59 patients with nonmalignant
cancers, 23 patients with renal anemia exhibited significantly
higher levels of VEGF in comparison to those of normemic
patients [24]. Furthermore, in a CKD population study
including patients at stages 3b-4, the adjusted linear inverse
association of the flow-mediated dilatation with hemoglobin
(Hb) in a range between 8.5 and 14.5 g/dL, demonstrated that
(Hb) per se affects the endothelial function regulation which
could likely determine the VV neovascularization [25, 26].
Since, to our knowledge, there are no reports describing
the adventitial VV density in patients with renal disease
nor the pathophysiology of adventitial VV density in this
population, the current study was designed to compare
the carotid adventitial VV density in CKD patients with
the physiological carotid adventitial VV density in healthy
volunteers with none of the classical risk factors. Moreover,
since, inflammation, high levels of PTH, vitamin D defi-
ciency, and anemia are generally observed features of CKD,
we examined the correlation of these variables, including
VEGF, with the carotid adventitial VV content in order to
evaluate their role in increasing the carotid adventitial VV,
therefore aggravating CV disease (CVD), in both dialysis and
nondialysis-dependent CKD patients.
2. Material and Methods
2.1. Study Subjects. In this single-centre, cross-sectional study,
81 patients with CKD (53%males; median age 60 [53.0; 66.0])
were enrolled as the case group according to a previous
selection of 104 CKD patients: patients were withdrawn from
the study because of poor or overly strong echogenicity or
because of poor or inaccessible venous access. Further exclu-
sion criteria included the following: (1) they experienced pre-
vious cardiovascular events such as coronary heart disease,
cerebrovascular disease, and peripheral vascular disease; (2)
they met the exclusion criteria for the administration of the
contrast agent including (a) recent cardiac instability, (b)
recent (<7 days) coronary intervention, (c) class III or IV
heart failure, (d) severe pulmonary hypertension, and (e)
allergic reaction to sulphur hexafluoride, the gas contained
in the contrast agent. Specifically, 44 patients belonged to
CKD stages 3-4, while 37 belonged to CKD stage 5D (28
hemodialysis patients and 9 peritoneal dialysis patients).
Sixty-five subjects with none of the classical risk factors for
cardiovascular disease (46% male; median age 49 [41; 57])
were enrolled as control group. The age range was between
30 and 70 years.
The study protocolwas approved by the ethical committee
at the University Hospital Arnau de Vilanova (HUAV, Lleida,
Spain). All subjects signed an informed consent prior to
morphometric parameter acquisition and blood drawing
after overnight fasting.
2.2. Morphometric and Biochemical Parameters. Morpho-
metric body parameters such as weight (kilograms) and
height (meters) were measured with a digital weight scale
equipped with a stadiometer. Body mass index (BMI) was
calculated as weight divided by the square of height. The
waist circumference (WC) was measured in the umbilicus
level (cm). While patients were seated and had rested for
ten minutes, systolic and diastolic blood pressure (SBP
and DBP) were obtained with an automated oscillometer
(Omron HEM-705CP) and calculated as the average of three
independent measurements. Serum levels of glucose, total
cholesterol (cholesterol), HDL and LDL cholesterol, triglyc-
erides (TG), and ultrasensitive C-reactive protein (CRP), cre-
atinine clearance (CC), calcium (Ca), phosphorous (P), PTH,
albumin (Alb), ferritin, hemoglobin (Hb), fibrinogen, and
leukocytes were obtained using the standard methods of the
laboratory of Clinical Biochemistry at the HUAV. For serum
VEGF, the Human VEGF ELISA Kit was used (R&D System,
DVE00). Serum levels of 25-hydroxyvitamin D (25D) were
measured using the Chemiluminescence Immunoassay on
the LIAISON XL Analyzer (DiaSorin), while serum 1,25D
levels were determined using a radioreceptor assay (Gamma-
B dihydroxyvitamin D, IDS Hybritec).
2.3. Standard and Contrast-Enhanced Carotid Ultrasound.
All subjects underwent a B-mode ultrasound examination of
the extracranial carotid arteries (CA). For the measurements
of carotid intima-media thickness (cIMT; mm) of the far
wall of the common carotid artery (CCA) 1 cm proximal
to the bifurcation and for the evaluation of atheromatous
plaque presence, a prior axial exploration was followed by
a longitudinal exploration. Carotid plaque was defined as a
cIMT > 1.5mm or as a focal thickening overpassing into the
arterial lumen by at least 50% of the surrounding cIMT value
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[27, 28]. Then, subjects underwent the contrast-enhanced
ultrasound (CEUS) imaging procedure using the contrast
agent SonoVue (Bracco Spa, Milan, Italy). The contrast agent
was prepared as recommended on the manufacturing data
sheet, and, for each CA explored, a 2.5mL contrast agent
bolus, followed by 10mL of a saline, was injected in the
antecubital vein (20-gauge needle). This chosen dose was the
lowest dose adequate to reach a strong and clear signal that
suffice to obtain statistically significant differences between
the adventitial VV signal in control subjects and CKD
patients based on the previous differences obtained between
type 2 diabetic patients with or without retinopathy and
control subjects [29].TheCEUS imaging was performedwith
a Siemens Sequoia 512 using the 15L8W linear array probe
(7Mhz) with a low mechanical index of 0.18. This device
is equipped with Cadence contrast pulse sequencing (CPS)
technology able to determine a high sensitivity and specificity
of contrast agent detection. All the videos were analyzed
using the Siemens software Syngo. Adventitial VV content
was measured as previously described [30]. Videos in which
signals (clipping artefacts) were observed in the far arterial
wall before contrast injection were excluded from reading.
Moreover, additional reasons for reading exclusion were as
follows: (1) the contrast agent which disappeared rapidly,
thus impeding proper visualization or (2) the presence of
an ultrasound shadow that impeded the reading in the area
under analysis.
Since the optimal cIMT measurement is obtained on
the far wall and because our applied method elicits strong
clipping artefacts in the near wall [31], in accordance with
other reports exploring the adventitial and intraplaque VV
[32–34], the VV signal was measured in the far wall as
well. Importantly, although the far wall could be liable to
imaging artefacts due to nonlinear propagation [35], there is
a licit expectation that these artefacts are similar for healthy
controls and CKD patients.
2.4. Statistical Analysis. Descriptive statistics of mean (stan-
dard deviation) or median [interquartile range] were esti-
mated for quantitative variables with a normal or nonnormal
distribution, respectively, while, for qualitative variables,
absolute and relative frequencies were used. Normal distri-
bution was analyzed using the Shapiro-Wilks test.
The significance of the differences in quantitative vari-
ables between groups (control, CKD stages 3-4, and CKD
stage 5D) was assessed by analysis of variance or Kruskal-
Wallis test depending on their normal distribution. The
significance of the differences in qualitative variables between
the three studied groups was assessed by Chi-squared test
or Fisher’s exact test in case of any expected frequency of
the corresponding contingency table lower than 5. In case
of significant differences, multiple testing adjusted pairwise
comparisons were performed using the Tukey or Benjamini-
Hochberg method according to a normal or not normal
distribution. Linear regression models were fitted to each
measure of cIMT and carotid adventitial VV in order to assess
differences between groups considering or not age as angio-
genic factor. The most adequate Box-Cox transformation
was applied in case of nonnormally distributed residuals
from multivariable regression models. Within the CKD
population, monotonic relationships of the right and left
carotid adventitial VV with quantitative characteristics were
assessed by using Spearman’s rank correlation coefficients. In
case of significant association, age-adjusted linear regression
models were fitted. Associations of the right and the left
carotid adventitial VV with dichotomous characteristics of
each CKD studied stage were assessed by Mann–Whitney 𝑈
test (Kruskal-Wallis test for smoking status). An adjusted lin-
ear regressionmodel was fitted to the right carotid adventitial
VV mean, including the assessment of the significant inter-
actions. Only interactions or main effects with a significant
contribution to the final model according to the likelihood
ratio test were included. All the studied variables (see Tables
1 and 5) were assessed for significant contribution into the
model. A significance level of 0.05 was fixed previously to
the statistical analysis of the study data with the freeware
statistical software R [36]. A figure to illustrate the estimated
right carotid adventitial VVmean and its confidence intervals
was performed to show the relationship with hemoglobin,
once adjusted by all the significant variables and their
interactions.
3. Results
Baseline characteristics of the study populations, controls (C)
and patients with chronic kidney disease at stages 3-4 and
5D, are shown in Table 1. According to disease characteris-
tics, subjects affected by CKD were significantly older than
subjects of the control group (𝑝 = 0.001, CKD 3-4 versus C;
𝑝 < 0.001, CKD 5D versus C). Moreover, as expected from
the inclusion criteria of the selected control population with
none of the classical risk factors for cardiovascular disease
and according to the disease characteristics, body mass index
(BMI, 𝑝 = 0.013, CKD 3-4 versus C), waist circumference
(WC, 𝑝 < 0.001, CKD 3-4 versus C; 𝑝 = 0.017, CKD 5D
versus C), serum glucose (𝑝 = 0.004, CKD 3-4 versus C),
triglycerides (TG, 𝑝 < 0.001, both CKD groups versus C),
systolic blood pressure (SBP, 𝑝 < 0.001, both CKD groups
versus C), and diastolic blood pressure (DBP,𝑝 < 0.001, CKD
3-4 versus C), as well as serum C-reactive protein (CRP, 𝑝 <
0.001, CKD5DversusC), were significantly higher in patients
with CKD. Additionally, serum 25-hydroxyvitamin D (25D)
levels and LDL cholesterol were lower in the CKD 5D group
than in the control group (𝑝 < 0.001 and𝑝 = 0.018, resp.).On
the other hand, serum VEGF levels were significantly higher
in both CKD groups than in control subjects (𝑝 = 0.004 and
𝑝 = 0.013). Finally, dialysis patients showed, in comparison
with nondialysis CKD patients, a significantly higher CRP
(𝑝 = 0.001) and lower levels of 25D (𝑝 < 0.001).
The analysis of the cIMT and of the carotid adventitial VV
showed that, after adjusting by the natural atherogenic factor
age, CKD 5D patients had a higher cIMT only in the right
carotid artery (Table 2: 𝑝 = 0.002 and 𝑝 = 0.043, CKD 5D
versus C and CKD 3-4, resp.), while the adventitial VV were
significantly higher only in the right carotid artery of CKD
patients at stages 3-4 (Table 2: 𝑝 = 0.007, CKD 3-4 versus C)
Tables 3 and 4 show the unadjusted associations between
the adventitial VV and biochemical/anthropometric and
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59.5 [52.8; 65.0] 60.0 [53.0; 68.0] <0.001 0.001 <0.001 0.214
Sex
Man 30 (46.2%) 27 (61.4%) 16 (43.2%) 0.189#
Women 35 (53.8%) 17 (38.6%) 21 (56.8%)
BMI (Kg/m2) 24.8
[22.9, 26.3]
27.8 [24.0; 30.7] 25.9 [23.7; 27.9] 0.010 0.013 0.130 0.151
WC (cm)∗ 88.6 ± 9.29 97.3 ± 12.4 94.8 ± 10.0 <0.001 <0.001 0.017 0.533
Glucose (mg/dL) 91.0
[87.0; 96.0]
100 [90.0; 113] 93.0 [84.0; 102] 0.009 0.004 0.928 0.088
Total cholesterol (mg/dL) 183 [162; 195] 181 [165; 206] 172 [148; 198] 0.353#
HDL cholesterol (mg/dL) 54.0
[45.0; 63.0]
50.0 [44.0; 61.0] 48.0 [41.0; 53.0] 0.087#
LDL cholesterol (mg/dL)∗ 111 ± 23.90 109 ± 28.9 95.3 ± 30.8 0.022 0.875 0.018 0.095
TG (mg/dL) 58 [48.0; 76] 128 [80.0; 153] 108 [84; 168] <0.001 <0.001 <0.001 0.857
SBP (mmHg) 121 [113; 132] 143 [134; 158] 140 [130; 158] <0.001 <0.001 <0.001 0.665
DBP (mmHg)∗ 74.7 ± 7.95 83.3 ± 10.6 78.1 ± 12.6 <0.001 <0.001 0.254 0.061
CRP (mg/L) 0.82
[0.50; 1.96]
1.38 [0.78; 3.65] 4.13 [2.27; 9.80] <0.001 0.099 <0.001 0.001
25D (ng/mL) 25.7
[20.2; 30.4]
28.1 [20.4; 33.0] 12.7 [8.80; 20.7] <0.001 0.556 <0.001 <0.001
VEGF (pg/mL) 233 [112; 372] 398 [230; 599] 373 [219; 507] 0.002 0.004 0.013 0.595
∗Identified variables with normal distribution. Values of these variables are described with mean ± standard deviation. For variables with significant deviations
fromnormal distribution, values are provided asmedian [IQR]. #Adjusted𝑝 values inmultiple comparisons are not performed for variables with nonsignificant
differences according to the overall test (𝑝 overall). BMI: body mass index; WC: waist circumference; TG: triglycerides; SBP: systolic blood pressure; DBP:
diastolic blood pressure; CRP: C-reactive protein; 25D: 25-hydroxyvitamin D; VEGF: Vascular Endothelial Growth Factor.
Table 2: Carotid IMT and carotid adventitial VV values in control subjects and patients affected by chronic kidney disease.
Control (𝑛 = 65) CKD 3-4(𝑛 = 44)
CKD 5D

















Left cIMT∗ 0.66 ± 0.13 0.72 ± 0.15 0.79 ± 0.16 <0.001(0.055b) 0.030 <0.001 0.053
B














∗Identified variables with normal distribution. Descriptive values are expressed as mean ± SD or median [IQR] depending on their normal distribution
according to Shapiro-Wilks test. #Adjusted 𝑝 values in multiple comparisons are not performed for variables with nonsignificant differences according to the
overall test (𝑝 overall).The column “LRT 𝑝” refers to the likelihood ratio test 𝑝 value measuring the overall differences among groups by comparing the models
with and without group identification. aBox-Cox transformation of the dependent variable to get normally distributed residuals from the multivariate linear
regression analysis. bAge adjusted 𝑝 value in linear regression analysis.
clinical variables known to be potentially involved in the
development of atheromatosis. As shown in Table 3, in CKD
patients at stages 3-4, the adventitial VV of both carotid
arteries did not correlate with any of the studied variables. On
the other hand, in patients at CKD stage 5D, the right adven-
titial VV positively andmonotonically associated with serum
glucose and HDL cholesterol (𝑝 = 0.0089 and 𝑝 = 0.0073,
resp.), while the left adventitial VV negatively associated with
serum calcium (𝑝 = 0.0072) and positively associated with
albumin (𝑝 = 0.0392). Nevertheless, when an age-adjusted
linear regressionmodel was applied, significantly higher right
adventitial VV were identified only for the second and the
third tertile of glucose levels (90–104 and 105–227mL/dL;𝑝 =
0.0241 and 𝑝 = 0.0099, resp.). This association is consistent
with the right adventitial VV significant association with
diabetes in dialysis patients (Table 4: 𝑝 = 0.038).
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Table 3: Association between adventitial VV and biochemical and anthropometric variables in CKD patients.
CKD 3-4 CKD 5D
Right VV Left VV Right VV Left VV
Correlation 𝑝 value Correlation 𝑝 value Correlation 𝑝 value Correlation 𝑝 value
Age (years) 0.0666 0.6913 −0.1730 0.3279 −0.0788 0.6790 0.2077 0.2708
WC (cm) 0.1106 0.5084 −0.0870 0.6245 −0.0627 0.7466 −0.1939 0.3064
BMI (Kg/m2) 0.1226 0.4635 −0.0212 0.9051 0.2107 0.2636 −0.1618 0.3931
Glucose (mg/dL) 0.2134 0.2183 −0.2012 0.2777 0.4691 0.0089 0.0726 0.7029
Cholesterol (mg/dL) 0.0507 0.7722 0.1797 0.3335 0.3547 0.0545 −0.2098 0.2658
HDL cholesterol
(mg/dL) −0.2872 0.0943 −0.1220 0.5133 0.5044 0.0073 0.1116 0.5871
LDL cholesterol
(mg/dL)∗ 0.1696 0.3301 0.0217 0.9076 0.2486 0.2111 −0.1562 0.4461
TG (mg/dL) 0.1711 0.3259 0.3021 0.0986 0.0974 0.6088 −0.1953 0.3009
SBP (mmHg) 0.0165 0.9215 −0.3020 0.0826 −0.1072 0.5945 −0.1881 0.3378
DBP (mmHg)∗ −0.1329 0.4262 −0.2240 0.2029 −0.0542 0.7885 −0.3296 0.0868
CRP (mg/L) 0.2230 0.3169 0.1123 0.6471 −0.0024 0.9898 0.0265 0.8898
Ca (mg/dL)∗ 0.0117 0.9468 0.0306 0.8702 0.0031 0.9869 −0.4805 0.0072
P (mg/dL) −0.0686 0.6943 −0.0157 0.9331 −0.2310 0.2193 −0.1963 0.2986
PTH (pg/mL) −0.3066 0.1649 −0.1738 0.4768 −0.1056 0.6000 −0.2124 0.2767
25D (ng/mL) 0.0902 0.6175 0.0874 0.6519 0.1395 0.4621 0.1600 0.3984
1,25D (pg/mL) 0.0089 0.9656 0.1404 0.5439 −0.2132 0.2667 0.0175 0.9311
Albumin (mg/dL)∗ −0.0547 0.7586 0.0710 0.7092 0.1052 0.5802 0.3785 0.0392
Ferritin (mg/dL) 0.0378 0.8680 −0.2115 0.3847 −0.2234 0.2354 −0.0476 0.8096
Hemoglobin (g/dL)∗ 0.0572 0.7518 −0.0715 0.7123 −0.3118 0.0935 0.0661 0.7286
Fibrinogen (g/L) 0.3145 0.0966 −0.0017 0.9934 0.0913 0.6439 0.1483 0.4515
Leukocytes (106/L) 0.2373 0.1835 −0.2228 0.2454 0.1861 0.3429 0.0889 0.6658
VEGF (pg/mL) 0.0645 0.7037 −0.3152 0.0740 0.2779 0.1370 0.2934 0.1224
∗Identified variables with normal distribution (Pearson’s correlation). For variables with significant deviations fromnormal distribution, Spearman’s correlation
was applied. Statistically significant 𝑝 values are indicated in bold. WC: waist circumference; BMI: body mass index; TG: triglycerides; SBP: systolic
blood pressure; DBP: diastolic blood pressure; CRP: C-reactive protein; Ca: serum calcium; P: serum phosphorus; PTH: parathyroid hormone; 25D: 25-
hydroxyvitamin D; 1,25D: 1𝛼,25-dihydroxyvitamin D; VEGF: Vascular Endothelial Growth Factor.
Since this was the main goal of the study, we further
explored if there were differences between the two CKD
groups in any of the characteristic variables of the disease
(Table 5). As a consequence of the disease stages, phosphorus
(P), ferritin, and PTH were higher in dialysis patients (𝑝 <
0.001; 𝑝 = 0.001; 𝑝 < 0.001, resp.). On the other hand,
serum calcium (Ca), 1,25D, and albumin were lower in
dialysis patients (𝑝 = 0.001; 𝑝 < 0.001 and 𝑝 < 0.006,
resp.). As expected, CKD patients on dialysis, due to the
high incidence of anemia, required more treatment with
erythropoiesis stimulating agents (ESA) and/or iron than
nondialysis patients (𝑝 < 0.001 and 𝑝 = 0.001, resp.), while
the level of hemoglobinwas lower than that in the nondialysis
patients (𝑝 < 0.001).
Finally, an adjusted linear regression model was fitted in
order to explore how the variables involved in angiogenesis
and CKD stage could contribute to the increase in the
adventitial VV content (Table 6). Specifically, significant dif-
ferences in the carotid adventitial VVwere determined by the
hemoglobin levels depending onwhether or not patientswere
on dialysis. As shown in Figure 1, the adjusted mean right
VV (RVV) was estimated to be statistically higher in CKD
nondialysis patients with hemoglobin levels of 12.5mg/dL or
above than in CKD nondialysis patients with hemoglobin
levels below 12.5mg/dL (0.91 versus 0.54; 𝑝 = 0.0104).
Furthermore, for hemoglobin levels of 12.5mg/dL or above,
CKD nondialysis patients showed an estimated mean RVV
higher than that for CKD dialysis patients (0.91 versus 0.66;
𝑝 = 0.0008).
In addition, two more variables significantly contributed
to the model: 1,25D and P (Table 6). Specifically, the levels
of 1,25D were related to the right carotid adventitial VV only
for those patients with low P levels (below its median value).
Consequently, the estimated mean RVV was statistically
different for CKD patients with low 1,25D and P below
4mg/dL compared to that of the patients with P levels above
4mg/dL (0.54 versus 0.36; 𝑝 = 0.039).
Furthermore, since ESA treatment is a recognized angio-
genic factor and it is associated with being on dialysis, the
difference between ESA users and nonusers in both CKD
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Table 4: Association between adventitial VV and clinical dichotomous variables in CKD patients.
Right VV Left VV
CKD 3-4 CKD 5D CKD 3-4 CKD 5D
Median [IQR] 𝑝 value Median [IQR] 𝑝 value Median [IQR] 𝑝 value Median [IQR] 𝑝 value
Sex
Man 0.69 [0.58; 0.81] 0.586 0.65 [0.54; 0.74] 0.645 0.60 [0.55; 0.66] 0.275 0.52 [0.44; 0.78] 0.708
Woman 0.68 [0.48; 0.78] 0.61 [0.51; 0.70] 0.56 [0.46; 0.65] 0.55 [0.42; 0.61]
Diabetes
No 0.65 [0.53; 0.79] 0.397 0.56 [0.51; 0.69] 0.038 0.59 [0.50; 0.66] 0.881 0.52 [0.43; 0.64] 0.604
Yes 0.73 [0.65; 0.88] 0.70 [0.68; 0.75] 0.57 [0.53; 0.65] 0.57 [0.46; 0.65]
Hypertension
No 0.86 [0.60; 0.90] 0.188 0.66 [0.55; 0.81] 0.534 0.69 [0.58; 0.79] 0.661 0.50 [0.47; 0.76] 0.604
Yes 0.67 [0.51; 0.78] 0.59 [0.53; 0.71] 0.58 [0.51; 0.65] 0.54 [0.42; 0.64]
Dyslipidemia
No 0.66 [0.58; 0.78] 0.921 0.57 [0.54; 0.75] 0.698 0.65 [0.56; 0.74] 0.155 0.55 [0.48; 0.60] 0.860
Yes 0.70 [0.50; 0.81] 0.63 [0.51; 0.69] 0.57 [0.48; 0.61] 0.50 [0.42; 0.80]
Smoking status







0.450Former smoker 0.53 [0.46; 0.64] 0.70 [0.54; 0.74] 0.68 [0.62; 0.79] 0.53 [0.48; 0.71]
Smoker 0.79 [0.71; 0.84] 0.56 [0.53; 0.57] 0.64 [0.59; 0.74] 0.47 [0.44; 0.49]
Differences in the right or the left adventitial VV distribution depending on sex, diabetes, hypertension, dyslipidemia, and smoking in nondialysis and dialysis
patients.
populations was explored: no differences in the right VV
associatedwith the use of ESA.Moreover, no significant inter-
action between ESA use and hemoglobin levels associated
with the right carotid adventitial VV (data not shown).
4. Discussion
This study demonstrated that only the right carotid artery
(CA) is characterized by higher cIMT and adventitial VV in
CKD patients than in control subjects. In addition, of high
relevance from the nephrologist’s point of view, this study
identified hemoglobin as the factor that, at levels of 12.5 g/dL
or above, determines the highest estimated adventitial VV of
the right carotid artery in CKD patients at stages 3-4.
Specifically, in our study population, after adjusting for
age, a natural atherogenic factor, the highest cIMT, was
observed only in the right carotid artery of CKD patients
undergoing dialysis, while the highest adventitial VV content
was observed in CKD patients at stages 3-4 suggesting the
carotid adventitial VV neoangiogenesis as the earliest step
in the intima-media thickening. The difference in cIMT
observed in the right carotid artery, but not in the left, is
in accordance with several clinical studies in which asym-
metrical differences between the left and the right cIMT
are modulated by altered biochemical and hemodynamic
parameters [37, 38]. For instance, Chaubey et al.’s findings
demonstrated that the difference in cIMT, higher in the left
than in the right carotid artery in normotensive subjects,
is attenuated when considering subjects with a mean blood
pressure higher than 90 mmHg. Moreover, divergent values
of the right and the left cIMT could be explained by the fact
that the left cIMT thickens every ten years after the age of
35, while the same trend occurs in the right cIMT ten years
later and it is correlated with hemodynamic parameters as
observed by Luo and colleagues [39]. Importantly, our results
demonstrated that, at earlier stages of CKD, the adventitial
VV content is also higher only in the right carotid artery
in comparison with that in the control population, probably
due to similar hemodynamic changes such as shear stress.
Previous studies in healthy individuals without classical
risk factors for atheromatosis demonstrated that the left
carotid adventitial VV correlated with age and the left cIMT,
explaining in part the earliest appearance of atheromatosis
lesions in the left carotid artery [30, 40]. Taken together, these
results underline the importance of differentiating between
the left and the right carotid artery not only in control
subjects or in the general population but also in patients
with known cardiovascular risk factors which could deter-
mine heterogeneous atheromatosis in different territories of
the vascular bed. Indeed, although the differences in the
two carotid arteries are scarcely investigated, some works
reported how local factors,mainly the geometry of the carotid
artery, may play a role in the heterogeneous atherosclerotic
lesion localization due to different blood flow patterns that
influence changes in the shear stress [41, 42].
Unfortunately, the role of the carotid adventitial VV in
CKD patients and the factors that modulate its content are
still unknown. Consequently, the aim of this study was to
explore not only the content of adventitial VV but also how
angiogenic factors that are modified in CKD could have been
involved in its increase.Therefore, since cIMT and adventitial
VV were higher in the right carotid artery of the overall CKD
population in parallel with higher levels of inflammation,
TG, glucose, and blood pressure, as well as with lower levels
of vitamin D, we evaluated the relationship between these
variables and VV content in both dialysis and nondialysis
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Table 5: Clinical and biochemical differences between nondialysis and dialysis CKD patients.
CKD 3-4 (𝑛 = 44) CKD 5D (𝑛 = 37) 𝑝 overall
Diabetes
No 35 (79.5%) 30 (81.1%) 1.000
Yes 9 (20.5%) 7 (18.9%)
Hypertension
No 5 (11.4%) 7 (18.9%) 0.522
Yes 39 (88.6%) 30 (81.1%)
Dyslipidemia
No 11 (25.0%) 14 (37.8%) 0.315
Yes 33 (75.0%) 23 (62.2%)
Etiology
Diabetes 4 (9.09%) 4 (10.8%)
0.296
Glomerular 6 (13.6%) 12 (32.4%)
Interstitial 9 (20.5%) 9 (24.3%)
Polycystic 7 (15.9%) 4 (10.8%)
Vascular 8 (18.2%) 3 (8.11%)
Unknown 10 (22.7%) 5 (13.5%)
Plaques
No 21 (47.7%) 13 (35.1%) 0.359
Yes 23 (52.3%) 24 (64.9%)
Right plaques
No 25 (56.8%) 17 (45.9%) 0.452
Yes 19 (43.2%) 20 (54.1%)
Left plaques
No 27 (61.4%) 21 (56.8%) 0.847
Yes 17 (38.6 %) 16 (43.2%)
Smoking
Nonsmoker 15 (50%) 23 (62.2%)
0.517Former smoker 7 (23.3%) 8 (21.6%)
Smoker 8 (26.7%) 6 (16.2%)
Patients on ESA treatment
No 42 (95.5%) 5 (14.7%)
<0.001
Yes 2 (4.5%) 29 (85.3%)
NESP dose (𝜇g/kg/week) 0.64 [0.62; 0.66] 0.33 [0.17; 0.57] 0.198
Patients on iron treatment
No 39 (88.6%) 17 (51.5%)
0.001Yes 5 (11.4%) 16 (48.5%)
Dose (g/month) 105 [100; 105] 102 [100; 250]
Ca (mg/dL)∗ 9.22 ± 0.41 8.84 ± 0.56 0.001
P (mg/dL) 3.62 [3.22; 4.29] 4.16 [3.71; 5.38] <0.001
PTH (pg/mL) 8.80 [6.80; 13.8] 29.7 [17.1; 47.7] <0.001
1,25D (pg/mL) 38.5 [21.0; 45.5] 5.90 [5.90; 10.2] <0.001
Albumin (mg/dL)∗ 4.46 ± 0.32 4.25 ± 0.32 0.006
Ferritin (mg/dL) 156 [59.2; 195] 293 [143; 468] 0.001
Hemoglobin (g/dL)∗ 13.8 ± 1.79 12.4 ± 1.15 <0.001
Fibrinogen (g/L) 4.25 [3.82; 4.68] 4.40 [4.10; 5.10] 0.232
Leukocytes (106/L) 6.29 [5.32; 8.58] 5.77 [4.46; 6.98] 0.056
REGICORE 4.00 [3.00; 5.50] 2.50 [1.75; 5.25] 0.283
Score 1.00 [1.00; 2.00] 1.00 [0.00; 2.00] 0.374
∗Identified variables with normal distribution. Values of these variables are described withmean ± standard deviation. For variables with significant deviations
from normal distribution, values are provided as median [IQR]. Statistically significant values are indicated in bold. NESP: darbepoetin; Ca: serum calcium;
P: serum phosphorus; PTH: parathyroid hormone; 1,25D: 1𝛼,25-dihydroxyvitamin D; REGICORE: REgistre GIronı´ del COR (cardiovascular risk chart).
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Table 6: Adjusted association between RVV and dialysis in CKD patients.
Coefficients Estimate Std. error Pr (>t)
(Intercept) 0.53955 0.14587 0.000623
Hb (g/dL) [11.5, 12.5) 0.11525 0.14998 0.446544
Hb (g/dL) ≥ 12.5 0.36840 0.13735 0.010411
Dialysis 0.17840 0.14382 0.221679
Hb (g/dL) [11.5, 12.5): dialysis −0.04890 0.17228 0.777940
Hb (g/dL) ≥ 12.5: dialysis −0.42202 0.15385 0.008912
1,25D (pg/mL) [12.1, 66.0] −0.17625 0.08000 0.033131
P (mg/dL) [4.00, 7.31] −0.10963 0.06917 0.120476
1,25D (pg/mL) [12.1, 66.0]: P (mg/dL) [4.00, 7.31] 0.24083 0.10556 0.027658
Multiple 𝑅-squared: 0.3592. Hb was recoded into three levels according to values 11.5 and 12.5 based on its relationship with RVV. Levels of 1,25D were recoded
into two levels according to theirmedian in the subsamplewithoutmissing values in the variables of themodel.Hb: hemoglobin; 1,25D: 1𝛼,25-dihydroxyvitamin
















Figure 1: Effect of hemoglobin and dialysis on the right carotid
adventitial VV. Hemoglobin at levels of 12.5 g/dL or above deter-
mines higher levels of the right carotid adventitial VV (RVV). Bars
and error bars represent the mean and the 95% CI of the RVV.
patients. The unadjusted analysis revealed that while the VV
of CKD patients at stages 3-4 did not correlate with any of
the studied biochemical or anthropometric parameters, all of
which are highly involved in the development of atheromato-
sis, the VV of patients on dialysis was positively associated
only with serum glucose levels at the second and third
tertile (90–104 and 105–227mg/dL) and positively associated
with diabetes. This result is in accordance with the increase
of carotid adventitial VV in type 2 diabetic patients with
hyperglycemia even in absence of retinopathy [29]. The lack
of association of VV with glucose in CKD patients at stages
3-4 characterized by higher glucose levels suggests that VV
increase is driven by distinct factors according to the stage of
the disease. Indeed, previous studies have demonstrated that
while, in the general population and CKD patients at stage
3, there was a significant interaction between smoking and
TG which were independently associated with atheromatosis
[43, 44], in patients at advanced stages, this association
was lost. Similar results, depending on the stages of the
disease and the interaction between biochemical and life
habit risk factors, were observed for CRP which only at CKD
stages 4-5 was associated with smoking, high phosphate, and
atheromatosis only at the highest tertile [44, 45]. Moreover,
these results are in agreement with Sampson and colleagues’
study that proved no remarkable variations of VV content
with respect to the range of measurements of systolic and
diastolic blood pressure [33]. On the contrary, our results do
not coincide with experimental evidence that supports a role
of LPS-induced inflammation and high TG in the increase of
adventitial VV measured by CEUS and histological analysis
in rabbits with atherosclerosis [46]. Indeed, although CKD
patients are characterized by elevated CRP and TG levels, this
is a transversal cohort study in which neither time nor levels
of exposure of the artery wall to biochemical parameters
have been taken into account. Therefore, in accordance with
the demonstration that the atheromatous process is driven
by specific risk factors according to the CKD stage [44],
an adjusted linear regression model was used to identify
the variables that could independently predict the increase
of the carotid adventitial VV accordingly whether or not
patients were on dialysis. This analysis demonstrated that Hb
levels interact with the dialysis status. Specifically, in CKD
patients at stages 3-4, hemoglobin higher than 12.5 g/dL is
a predictor of an estimated higher adventitial VV of the
right artery. Although a high percentage of CKD patients
were under ESA treatment, especially those being on dialysis,
no difference in the adventitial VV content was associated
with the use of ESA. Therefore, the hemoglobin status in
our CKD nondialysis study population patients could be
considered a natural angiogenic mediator. This is of high
relevance in nephrology, since anemia greatly influences
cardiovascular outcomes. For instance, in Vlagopoulos et al.’s
study, in which four community-based trials were pooled,
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it was reported that, in CKD patients with anemia, the
risk of CVD was 1.7-fold higher [47]. On the other hand,
intervention with ESA for the correction of renal anemia
might increase occurrence of CVD. In fact, in the CREATE
study, the complete correction of anemia did not delay
the onset of cardiovascular events [48]. Moreover, in the
CHOIR study, target Hb level of 13.5 g/dL in nondialysis
CKD patients were associated with increased risk for death,
myocardial infarction, and cardiovascular events [48, 49].
Important to support our results is the demonstration by
Yilmanz et al. that nondiabetic CKDpatients at stages 3-4, not
using erythropoietin-based agents, showed a reduction of the
flow-mediated dilatation for hemoglobin levels higher that
11.6 g/dL.This is in contrastwith the finding of the prospective
and observational Dialysis Outcomes and Practice Patterns
Study in which the authors showed that the natural increase
of Hb to concentration >12 g/dL in hemodialysis patients did
not associate with increased mortality, suggesting that high
Hb levels per se are not harmful for CKD patients [50].
The interaction of 1,25D and P in the estimation of the
adventitial VVof the right carotid artery is intriguing. Indeed,
calcitriol is inversely correlated with the carotid adventitial
VV and is statistically different only for P levels below
its median value (4mg/dL). This apparent contradiction
could be due to the vitamin D supplementation, paricalcitol
treatment, and also the P-binding treatment that were not
taken into account in the present study.
As has been noted, this limitation of study could be
related to the administration of paricalcitol which could have
a direct effect on angiogenesis [51], inflammation [52] and
bone mineral metabolism, and above all PTH [53], while
the serum levels of active vitamin D cannot be measured
except for the calcitriol form. Further studies on a larger
sample size are needed to clarify the role of 1,25D and P on
VV angiogenesis. In addition to the low number of patients,
the present study is a cross-sectional study, the reason why
there is no indication on how the factors taken into account
contributed to a temporal relationship between exposure to
these risk factors and the increase of VV. Therefore, a future
study should be designed to evaluate the outcomes over time,
also taking into account the time of exposure to treatment.
Moreover, according to our results, the lack of hemoglobin
levels and bonemineralmetabolism in the control population
impeded the evaluation of the physiological association of
these parameters with neoangiogenesis in a healthy popula-
tion.
Despite these limitations, this study not only confirms
the strength of the use of CEUS in measuring adventitial
VV as a predictor of the atheromatous process based on the
fact that there is a high object evaluation of the imaging
(high intraobserver reproducibility) but also is a further
confirmation of the importance of separately evaluating the
left and the right carotid artery. Moreover, this study, to our
knowledge, is the first measuring the carotid adventitial VV
in a CKD population and the first indicating that Hb levels
and the interaction of 1,25D and P could be associated with
the carotid adventitial VV in this population.
In conclusion, this work suggests that, in CKD patients
at stages 3-4, hemoglobin levels higher than 12.5 g/dL might
be a cause for the increased adventitial VV of the right CA
that consequently could increase the right cIMT. Therefore,
it could be speculated that the higher incidence of athero-
matous disease in CKD patients could be driven by a higher
incidence of microangiopathy of the common carotid wall
driven by the hemoglobin status. Indeed, this could explain
why Hb levels as in the CHOIR study associated with higher
cardiovascular events and risk of death [49]. Consequently,
as previously specified, a longitudinal study with a higher
number of patients is required to evaluate the relationship of
Hb levels and the carotid adventitial VV in the onset of the
process of atheromatosis and cardiovascular events in CKD
patients.
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